BCEL vs. GOVX, PHIO, CLVR, PHAS, ALZN, REVB, EVOK, ARTL, ARDS, and BPTSY
Should you be buying Atreca stock or one of its competitors? The main competitors of Atreca include GeoVax Labs (GOVX), Phio Pharmaceuticals (PHIO), Clever Leaves (CLVR), PhaseBio Pharmaceuticals (PHAS), Alzamend Neuro (ALZN), Revelation Biosciences (REVB), Evoke Pharma (EVOK), Artelo Biosciences (ARTL), Aridis Pharmaceuticals (ARDS), and Biophytis (BPTSY). These companies are all part of the "pharmaceutical preparations" industry.
Atreca (NASDAQ:BCEL) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk and media sentiment.
Atreca currently has a consensus price target of $4.00, indicating a potential upside of 4,339.51%. GeoVax Labs has a consensus price target of $120.00, indicating a potential upside of 7,194.83%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts clearly believe GeoVax Labs is more favorable than Atreca.
Atreca's return on equity of -157.90% beat GeoVax Labs' return on equity.
GeoVax Labs has higher revenue and earnings than Atreca. GeoVax Labs is trading at a lower price-to-earnings ratio than Atreca, indicating that it is currently the more affordable of the two stocks.
Atreca has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 2.91, meaning that its stock price is 191% more volatile than the S&P 500.
In the previous week, Atreca and Atreca both had 1 articles in the media. Atreca's average media sentiment score of 0.00 equaled GeoVax Labs'average media sentiment score.
37.5% of Atreca shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 11.3% of Atreca shares are owned by company insiders. Comparatively, 5.7% of GeoVax Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Atreca received 84 more outperform votes than GeoVax Labs when rated by MarketBeat users. However, 91.67% of users gave GeoVax Labs an outperform vote while only 67.86% of users gave Atreca an outperform vote.
Summary
Atreca and GeoVax Labs tied by winning 7 of the 14 factors compared between the two stocks.
Get Atreca News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
